6 trends in life sciences investment this week
From 5 November 2026 to 11 November 2026, 18 biotech and health care companies reported $305.3 million of new private money in SEC Form D filings (company count down 23% on the 4-week average of 23.3), and companies registered 50 new trials, 17 of them at Phase 3.
As of . Research from public records, not investment advice.
- Venture money into biotech and health care: 18 operating companies reported Form D sales, $305.3 million in total. Companies down 23% on the 4-week average of 23.3; money up 95% on the 4-week average of $156.4 million.Source: SEC Form D
- Largest biotech or health care raise: Zai Lab Ltd sold $249.9 million. Biotechnology, Form D filed 9 November 2026.Source: SEC Form D
- New company-sponsored trials: 50 registered. Down 9% on the 4-week average of 54.8.Source: ClinicalTrials.gov
- New company-sponsored Phase 3 trials: 17 registered. Down 17% on the 4-week average of 20.5.Source: ClinicalTrials.gov
- Medicines stepping up a phase: 1 medicines entered a higher trial phase. Tuesday's list has the 12 largest.Source: ClinicalTrials.gov
- Disease with the most new company trials: Obesity, 4 new trials.Source: ClinicalTrials.gov
How this list is made
Each line compares the 7 days to yesterday with the average of the 4 weeks before; a line is left out while its source has no record for the week yet. Raises are SEC Form D sales by operating biotech, pharmaceutical and health care companies (funds and vehicles left out). Trials are registrations on ClinicalTrials.gov; approvals, clearances and warning letters come from FDA records.
Sources: SEC EDGAR, Form D, ClinicalTrials.gov, FDA.